A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis

SIMPLE SUMMARY: This study is one of the very few phase I trials on intraperitoneal chemotherapy applied as PIPAC. Cisplatin and doxorubicin may be safely used as PIPAC at a dose of 30 mg/m(2) and 6 mg/m(2), respectively; oxaliplatin can be used at an intraperitoneal dose of 135 mg/m(2). No serious...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancers (Basel)
Main Authors: Robella, Manuela, De Simone, Michele, Berchialla, Paola, Argenziano, Monica, Borsano, Alice, Ansari, Shoeb, Abollino, Ornella, Ficiarà, Eleonora, Cinquegrana, Armando, Cavalli, Roberta, Vaira, Marco
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7958944/
https://ncbi.nlm.nih.gov/pubmed/33802269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051060
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares